Public Comments - Revised Interim Guidelines for Examination

Public Comments on the United States Patent and Trademark Office
"Revised Interim Guidelines for Examination of Patent Applications
Under the 35 U.S.C. § 112, ¶1 ‘Written Description’ Requirement"
64 FR 71427, Dec. 21, 1999

NOTE: Comments submitted in electronic form were reformatted for margin and font consistency. Comments submitted on paper were scanned. Comments were listed alphabetically by individuals and then by organizations. Comments that addressed both the Utility and the Written Description Guidelines have been reproduced in both comment packages.

Comment 1	Cristina Azevedo
Comment 2	Karen S. Bentley
Comment 3	Philip L. Bereano
Comment 4	Alder S. Bourinbaiar
Comment 5	Elizabeth Bravo
Comment 6	Richard Broome
Comment 7	Don Burgett
Comment 8	W. Robinson H. Clark et al.
Comment 9	Liberty Coates
Comment 10	Gary Colby
Comment 11	Iver Cooper
Comment 12	George Corey
Comment 13	Deirdre Cummings
Comment 14	Jill Davies
Comment 15	Stanislaus J. Dundon
Comment 16	Samuel S. Epstein
Comment 17	Paul Fehlner
Comment 18	Laurie Ferreri
Comment 19	Thomas G. Field, Jr.
Comment 20	Bill Freese
Comment 21	Barry Hindmarch
Comment 22	Helen Jones
Comment 23	Gary Kah
Comment 24	Jonathan King
Comment 25	Christian Lacoste
Comment 26	Herbert Lass
Comment 27	Rod Leonard
Comment 28	Glenda Lindsay
Comment 29	Ann Lindsey
Comment 30	Mezzored@aol.com
Comment 31	Ed Muniak
Comment 32	Nell Newman
Comment 33	Frances Oliver
Comment 34	Steve Openshaw
Comment 35	Valerie J. Phillips
Comment 36	Harris A. Pitlick
Comment 37	Mora Rogers
Comment 38	Kate Savannah
Comment 39	Donald Sawyer
Comment 40	Belia Schuurman
Comment 41	Andrew Taynton
Comment 42	Jesus Juanos i Timoneda
Comment 43	John O. Tresansky
Comment 44	Carlos A. Vicente
Comment 45	Sally Whelan
Comment 46	Kelley Wiley
Comment 47	Mary Wiley
Comment 48	Warren D. Woessner
Comment 49	American Bar Association, Section of Intellectual Property Law/ Gregory J. Maier
Comment 50	American College of Medical Genetics/ R. Rodney Howell
Comment 51	American Intellectual Property Law Association/ Louis T. Pirkey
Comment 52	American Society of Human Genetics/ Ronald Worton
Comment 53	Association of American Medical Colleges/ Jordan J. Cohen
Comment 54	BioIndustry Association / Andrew G. Sheard
Comment 55	Biotechnology Industry Organization / Charles E. Ludlam
Comment 56	Boston Women's Health Book Collective / Anna M. Pohl
Comment 57	Council for Responsible Genetics / Claire Nader
Comment 58	Eli Lilly and Co. / Amy E. Hamilton
Comment 59	Genentech, Inc. / Sean A. Johnston
Comment 60	Genzyme Corporation / Steve Lazar
Comment 61	MJ Research, Incorporated / Michael Finney
Comment 62	National Association of Patent Practitioners / Joy Bryant
Comment 63	National Breast Cancer Coalition / Fran Visco
Comment 64	National Institutes of Health / Jack Spiegel
Comment 65	National Organization for Rare Disorders, Inc. / Abbey S. Meyers
Comment 66	Physicians and Scientists for Responsible Genetics, New Zealand / Jean Anderson

Some contents linked to on this page require a plug-in for PDF file.